Fierce Pharma Asia—Hengrui’s global plan; Merck, Kelun’s $1.4B cancer deal; Dr. Reddy’s Russia businessnews2022-05-20T10:18:12+00:00May 20th, 2022|Fierce Pharma|
Calliditas, with a fresh approval for Tarpeyo in hand, launches IgA kidney disease education campaignnews2022-05-20T09:10:04+00:00May 20th, 2022|Fierce Pharma|
‘The Top Line’ podcast: The aftermath of Roche’s failed TIGIT, Big Pharma’s Q1 growth vs. mRNA stars, plus this week’s headlinesnews2022-05-19T17:43:33+00:00May 19th, 2022|Fierce Pharma|
Catalent throws down $175M on yet another manufacturing expansionnews2022-05-19T17:10:44+00:00May 19th, 2022|Fierce Pharma|
Unlocking Patient Access and Product Success in a Digital Healthcare Worldnews2022-05-19T15:58:21+00:00May 19th, 2022|Fierce Pharma|
After Big Pharma pulls back in Russia, Dr. Reddy’s says business is boomingnews2022-05-19T14:54:47+00:00May 19th, 2022|Fierce Pharma|
Eli Lilly revs up immunology engine as Olumiant cruises toward coveted alopecia green lightnews2022-05-19T14:22:03+00:00May 19th, 2022|Fierce Pharma|
As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine ordernews2022-05-19T13:52:25+00:00May 19th, 2022|Fierce Pharma|
The Path to a More Data-Driven Understanding of the Specialty Drug Patient Journeynews2022-05-19T13:21:37+00:00May 19th, 2022|Fierce Pharma|
Syringe maker ApiJect reels in $111M in private investment roundnews2022-05-19T12:23:20+00:00May 19th, 2022|Fierce Pharma|
